As the name suggests, smid-cap stocks have a valuation between $200 million and $20 billion. The definition is pretty ...

We recently compiled a list of the 10 Hottest Mid-Cap Stocks So Far in 2025. In this article, we are going to take a look at ...

Insights into the digital tools that can help improve patient engagement and advance understanding in deep vein thrombosis ...

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins. See ...

Inari Medical Inc., one of Orange County’s fastest-growing medical device makers, is being acquired for $4.9 billion by ...

We recently published an article titled These 10 Firms Led This Week’s Rally. In this article, we are going to take a look at ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral. Analyst Price Forecast Suggests 14.00% Downside As of December 23, 2024, ...

We recently published a list of 10 Firms Post Strong Gains Amid Wall Street Bloodbath. In this article, we are going to take ...

Inari shareholders are getting a fair price relative ... risks and costs of thrombolytic therapy (drugs meant to break up clots) and a growing database on the safety and efficacy of mechanical ...

based Stryker has offered $4.9 billion to buy Inari Medical Inc., a California company that specializes in equipment for venous thromboembolism (VTE) systems to treat blood clots such as pulmonary ...

The deal for Inari bolsters Stryker's efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases.

Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic ...